Sissetulev kiriAvalik
Euroopa farmakopöa töökava asjus
Ravimiamet · 5. märts 2025
- Viit
- REP-1/1198-1
- Registreeritud
- 5. märts 2025
- Dokumendi liik
- Sissetulev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Saabumis/saatmisviis
- e-post
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2025
- Vastutaja
- Signe Leito (RA, Peadirektori asetäitja valdkond, Labor)
Sisu (failidest)
Signe Leito
Saatja: [email protected]
Saatmisaeg: kolmapäev, 5. veebruar 2025 17:17
Adressaat: Signe Leito
Teema: Proposed addition of a new monograph to the work programme of Group 10A: Thalidomide: EDQM-2025-00602-mail
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
Please make sure to include in any reply our mail reference: EDQM-2025-00602-mail
****************************************************************************
European Pharmacopoeia Commission Secretariat
RZ/PH/ 2025-00590L Strasbourg, 5 February 2025
JSB/mk
FOR THE ATTENTION OF NPAs
Copy: Presidium
Dear Colleagues,
Please find below the link to a survey being carried out concerning the proposed addition of the monograph Thalidomide to the work programme of Group
10A.
In order to have access to the survey, please copy and paste this link into your Internet browser:
https://survey.edqm.eu/index.php?r=survey/index&sid=173761&lang=en
Deadline for replies: 7 March 2025
With kind regards,
On behalf of Dr Jaume SANZ-BISET
1
Mireille KOPF
Assistant - European Pharmacopoeia Department EDQM - Council of Europe
7 Allee Kastner Cs-30026
F-67081 Strasbourg France
Tel. : +33 (0)3 88 41 28 53
[email protected]
www.edqm.eu
****************************************************************************
Please make sure to include in any reply our mail reference: EDQM-2025-00602-mail
2